The present invention is directed to a compound comprising at least one phosphepine ring and having the phosphorous atom of the phosphepine ring substituted with at least one monovalent substituent R, wherein (i) R is selected from aryls and heteroaryls comprising at least two rings or (ii) R is selected from aryls, alkyls, heteroalkyls, heteroaryls, H, F, CI, Br, I, OH, and OR*, wherein R* is selected from C1-C22 alkyl and C7-C22 arylalkyl, and the hosphepine ring is a ring according to formula (I), wherein structural moieties A, B, C are independently selected from ortho-arylenes and ortho-heteroarylenes, with the proviso that neither A nor B is a condensed arylene, and C comprises at least two annelated rings, a semiconducting material comprising this compound as well as an electronic device comprising the semiconducting material.

This invention relates to compounds that are useful as cancer therapies. The compounds comprise azithromycin derivatives having a phosphonium cation tethered to the azithromycin macrocycle. The invention also relates to methods of using said compounds and the pharmaceutical formulations comprising said compounds.

The present specification provides a compound having a spiro structure and an organic light emitting device including the same.

A P2X3 and/or P2X2/3 receptor antagonist of formula (I), a pharmaceutical composition comprising the same, and a use thereof in preparing a drag for preventing or treating a disease mediated by the P2X3 and/or P2X2/3 receptor antagonist.

##STR00001##

The present disclosure provides a boron-heterocyclic compound having a structure represented by Chemical Formula 1, in which L.sub.1 and L.sub.2 are each independently selected from a single bond, C6-C30 aryl, C6-C30 fused aryl, C4-C30 heteroaryl, or C4-C30 fused heteroaryl; and R.sub.1 and R.sub.2 are each independently selected from carbazolyl and derivative groups thereof, acridinyl and derivative groups thereof, and diarylamino and derivative groups thereof. In an embodiment, the boron-heterocyclic structure is suitable for use not only as an electron acceptor group but also as a linking group. By linking a group having a large steric hindrance to the boron atom of the boron-heterocyclic ring, the compound molecules are prevented or limited from aggregating, and thus a π-aggregation or excimer formed by direct accumulation of conjugate planes is avoided or reduced, thereby improving luminous efficiency. The present disclosure further provides a display panel and a display apparatus containing the compound.

##STR00001##

A compound of the following structure is provided:

##STR00001##

The presently-disclosed subject matter describes distorted gold (I) phosphine compounds. The presently-disclosed subject matter also describes a method for killing fungus comprising contacting fungus with distorted gold (I) phosphine compounds. The presently-disclosed subject matter further describes a method of preventing or disrupting a biofilm on a surface comprising contacting a surface with distorted gold (I) phosphine compounds.

The invention relates to oligomerization of olefins, such as ethylene, to higher olefins, such as a mixture of 1-hexene and 1-octene, using a catalyst system that comprises a) a source of chromium b) one or more activators and c) a phosphacycle-containing ligating compound. Additionally, the invention relates to a phosphacycle-containing ligating compound and a process for making said compound.

The invention relates to oligomerization of olefins, such as ethylene, to higher olefins, such as a mixture of 1-hexene and 1-octene, using a catalyst system that comprises a) a source of chromium b) one or more activators and c) a phosphacycle-containing ligating compound. Additionally, the invention relates to a phosphacycle-containing ligating compound and a process for making said compound.

The invention relates to oligomerization of olefins, such as ethylene, to higher olefins, such as a mixture of 1-hexene and 1-octene, using a catalyst system that comprises a) a source of chromium b) one or more activators and c) a phosphacycle-containing ligating compound. Additionally, the invention relates to a phosphacycle-containing ligating compound and a process for making said compound.